相关实验视频

Updated: Jul 25, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

肠道微生物组会影响HER2阴性晚期胃癌治疗的反应

Zihan Han^1,2, Siyuan Cheng^1,3, Die Dai⁴

¹Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.

Clinical and translational medicine

|June 29, 2023

概括

肠道微生物组对HER2阴性胃癌的治疗反应的影响根据治疗不同. 较高的乳酸菌丰度与更好的免疫疗法反应相关,表明其作为辅助治疗的潜力.

科学领域:

在瘤学瘤学.
微生物组研究微生物组研究
胃肠病学胃肠病学

背景情况:

转移性/不可切除的HER2阴性胃癌的治疗包括化疗和免疫疗法,但药物耐药性是一个重大挑战.
了解影响治疗疗效的因素对于改善晚期胃癌患者的治疗结果至关重要.

研究的目的:

调查肠道微生物组特征在预测HER2-阴性晚期胃癌治疗反应中的作用.
分析肠道微生物组组成如何在接受化疗,免疫疗法或组合疗法的患者之间有所不同.

主要方法:

对117名患有HER2-阴性晚期胃/胃食道结腺癌的患者进行了元基因组学测序,这些患者接受了不同的治疗方案.
根据治疗疗效,患者被分为响应者和不响应者.
在基线和整个治疗过程中分析了肠道微生物组特征,研究结果在101名患者的独立队列中得到了验证.

主要成果:

不同的肠道微生物群签名与化疗,免疫疗法和组合疗法组的临床反应有关.
在每个治疗组中,响应者和不响应者之间,特定的微生物物种存在显著差异.
乳酸菌的较高丰度与增加的微生物群多样性和对抗PD-1/PD-L1免疫疗法的显著更好的反应有关,并趋向于改善无进展生存率.

结论:

肠道微生物组以治疗特定的方式影响HER2-阴性晚期胃癌的治疗反应.
免疫疗法和化疗的结合不仅仅等同于每个模式的附加效应.
乳酸菌表明作为一种新型辅助剂的承诺,以提高胃癌治疗中的免疫疗法疗效.

关键词:

化学疗法化疗化疗胃癌胃癌是一种胃癌.我们的肠道微生物组.免疫疗法免疫疗法

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model

Published on: February 28, 2018

相关概念视频

What is Monogastric Digestion?

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...